Skip to main content
OpenTrials
Completed

NCT Number: NCT01493037

PICSO in Patients With STEMI Treated by Primary Percutaneous Coronary Intervention

A prospective multi-center study in which patients with an acute heart attack (in the left anterior descending artery) with ECG changes (ST segment elevation) receive angioplasty followed by stent placement and 90 minutes of PICSO treatment. This is a proof of concept study designed to document the safety and feasibility of the Pressure Controlled Intermittent Coronary Sinus Occlusion (PICSO) Impulse system.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Academic Medical Center - University of Amsterdam, Amsterdam, Netherlands

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • First time anterior STEMI defined by the following:
  • Symptoms of myocardial ischemia > 30 minutes and < 12 hours
  • ST-segment elevation > 1mm (> 0.1 mV) in two contiguous precordial leads in the anterior territory on a 12-lead ECG
  • Uncomplicated PCI of a LAD culprit lesion (defined as angioplasty followed by stent placement or direct stenting without the occurrence of an adverse event(s) that would preclude further study participation, such as major bleeding, perforation, hypotension, pulmonary edema or instability that in the judgement of the investigator preclude participation in the trial)

Exclusion criteria

  • Younger than 18 years of age
  • Hospitalization with a primary diagnosis of acute myocardial infarction (AMI) previously or has evidence of previous Q-wave infarct
  • Left main coronary artery culprit lesion
  • Additional stenosis in the LAD for which PCI or CABG is likely to be needed in the next 6 months and which is not treated during the index procedure
  • Cardiogenic shock (systolic blood pressure ≤90 mmHg in spite of conservative measures) or pulmonary edema (O2 saturation <90% by pulse oximetry and the presence of rales or crackles)
  • Cardiac arrest requiring chest compression or resuscitation
  • Anatomical complications limit capacity to place PICSO Impulse device or achieve stable catheter placement or occlude coronary sinus
  • Known renal disease (GFR < 30 mL/min/1.73m2) or dialysis
  • History of stroke, TIA or reversible ischemic neurological disease within last 6 months
  • Left bundle branch block
  • Known contra-indication for magnetic resonance imaging (Metallic implant precluding MRI, claustrophobia, obesity precluding MRI, etc.)
  • Presence of any lead in the coronary sinus
  • Active or treated malignancies in the last 12 months
  • Previous coronary artery bypass graft surgery
  • Known severe anemia (Hgb < 10 g/dL or < 6.2 mmol/L)
  • Known platelet count < 100,000, known coagulopathy or bleeding diathesis, or unwilling to accept transfusions
  • Participation in another ongoing clinical study
  • Women of child-bearing age
  • Non-cardiac comorbidities and life expectancy < 1 year
  • Legal incompetence
  • A condition that, in the opinion of the Investigator, precludes participation, including compliance with all follow-up procedures
  • No dependents neither to the sponsor nor to the investigator

Treatment and study plan

PICSO (Pressure-controlled Intermittent Coronary Occlusion

Device

The PICSO catheter has a balloon which is placed in the coronary sinus via the femoral vein. The balloon is inflated and deflated at intervals calculated by an algorithm and adjusted according to the patient's own coronary sinus pressure plateau.

Other names: PICSO Impulse Catheter, PICSO Impulse Console

Primary outcomes

  1. Successful delivery of PICSO treatment

    Time frame: 90 minutes

    Assessment of the feasibiity of PICSO in STEMI patients defined as the successful elivery of the PICSO catheter and the successful administration of PICSO treatment for 90 minutes

Secondary outcomes

  1. MRI measurement of infarct size

    Time frame: 4 months

    Infarct size assessed by cardiac MRI between 2-5 days post primary PCI and again at 120 days follow up

  2. Assessment of left ventricular function

    Time frame: 4 months

    Left ventricular function assessed by echocardiography between 2-5 days after primary PCI and at 120 days

  3. Assessment of microvascular perfusion

    Time frame: 4 months

    Microvascular perfusion assessed by cardiac MRI between 2-5 days after primary PCI and at 120 days

  4. Resolution of ST-segment elevation

    Time frame: 24 hours

    Occurrence of complete resolution of ST-segment elevation 30, 60, 90 and 120 minutes after last contrast injection prior to PICSO placement procedure on 24 hour continuous 12 lead ECG Holter monitor recording

  5. Measurement of ST segment time curve area

    Time frame: 3 hours

    ST segment time curve area for the first 3 hours on 24 hour continuous 12 lead ECG Holter monitor recording.

  6. Number of adverse events

    Time frame: 6 months

    Safety endpoints recorded are Major Adverse Cardiac Events (MACE), Major Adverse Cardiac and Cerebrovascular Events (MACCE), net adverse clinical events (MACE and bleeding), Serious and non serious Adverse Device Events ((S)ADE) rates

Sponsors and collaborators

Lead sponsor

Miracor Medical SA

Industry

Registry information

Official study title

Pressure Controlled Intermittent Coronary Sinus Occlusion in Patients With ST Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention: Safety and Feasibility Study

Acronym: pRAMSES

Important dates

Study start
2011
Primary completion
2014
First posted
Dec 15, 2011
Registry last updated
Jul 16, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.